Gastrooesophageal cancer+1
Not recruitingStudy on 68Ga-FAPI-46 and Fludeoxyglucose (18F) for Diagnosing Stomach and Gastroesophageal Junction Cancer in Patients Undergoing Chemotherapy
Study on 68Ga-FAPI-46 and Fludeoxyglucose (18F) for Diagnosing Stomach and Gastroesophageal Junction Cancer in Patients Undergoing Chemotherapy
- Disease:Gastrooesophageal cancerGastric cancer
- Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)TriacetateFludeoxyglucose (18F)
Denmark- Participants:18–64 years · 65+ years
- Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate









